APA
Coleman R. L., Oza A. M., Lorusso D., Aghajanian C., Oaknin A., Dean A., Colombo N., Weberpals J. I., Clamp A., Scambia G., Leary A., Holloway R. W., Gancedo M. A., Fong P. C., Goh J. C., O'Malley D. M., Armstrong D. K., Garcia-Donas J., Swisher E. M., Floquet A., Konecny G. E., McNeish I. A., Scott C. L., Cameron T., Maloney L., Isaacson J., Goble S., Grace C., Harding T. C., Raponi M., Sun J., Lin K. K., Giordano H. & Ledermann J. A. (20180928). Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial. : Lancet (London, England).
Chicago
Coleman Robert L, Oza Amit M, Lorusso Domenica, Aghajanian Carol, Oaknin Ana, Dean Andrew, Colombo Nicoletta, Weberpals Johanne I, Clamp Andrew, Scambia Giovanni, Leary Alexandra, Holloway Robert W, Gancedo Margarita Amenedo, Fong Peter C, Goh Jeffrey C, O'Malley David M, Armstrong Deborah K, Garcia-Donas Jesus, Swisher Elizabeth M, Floquet Anne, Konecny Gottfried E, McNeish Iain A, Scott Clare L, Cameron Terri, Maloney Lara, Isaacson Jeff, Goble Sandra, Grace Caroline, Harding Thomas C, Raponi Mitch, Sun James, Lin Kevin K, Giordano Heidi and Ledermann Jonathan A. 20180928. Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial. : Lancet (London, England).
Harvard
Coleman R. L., Oza A. M., Lorusso D., Aghajanian C., Oaknin A., Dean A., Colombo N., Weberpals J. I., Clamp A., Scambia G., Leary A., Holloway R. W., Gancedo M. A., Fong P. C., Goh J. C., O'Malley D. M., Armstrong D. K., Garcia-Donas J., Swisher E. M., Floquet A., Konecny G. E., McNeish I. A., Scott C. L., Cameron T., Maloney L., Isaacson J., Goble S., Grace C., Harding T. C., Raponi M., Sun J., Lin K. K., Giordano H. and Ledermann J. A. (20180928). Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial. : Lancet (London, England).
MLA
Coleman Robert L, Oza Amit M, Lorusso Domenica, Aghajanian Carol, Oaknin Ana, Dean Andrew, Colombo Nicoletta, Weberpals Johanne I, Clamp Andrew, Scambia Giovanni, Leary Alexandra, Holloway Robert W, Gancedo Margarita Amenedo, Fong Peter C, Goh Jeffrey C, O'Malley David M, Armstrong Deborah K, Garcia-Donas Jesus, Swisher Elizabeth M, Floquet Anne, Konecny Gottfried E, McNeish Iain A, Scott Clare L, Cameron Terri, Maloney Lara, Isaacson Jeff, Goble Sandra, Grace Caroline, Harding Thomas C, Raponi Mitch, Sun James, Lin Kevin K, Giordano Heidi and Ledermann Jonathan A. Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial. : Lancet (London, England). 20180928.